EXCEED THE SPACE PROVIDED. Metabotropic Glutamate Receptors in Neurodegeneration The genetic basis for Huntington's disease (HD) is a CAG repeat expansion that encodes an expanded polyglutamine repeat in the huntingtin protein. However, the normal function of the huntingtin protein, and how the mutant protein leads to disease, is still unknown. Dysregulation of glutamatergic signaling pathways has long been implicated in many disease processes of the nervous system, and there is considerable evidence that abnormal glutamate receptor function contributes to disease pathogenesis in HD. Both ionotropic and metabotropic glutamate receptors have been implicated in the neurodegenerative process, but the unacceptable side effects of drugs targeting ionotropic glutamate receptors have limited their use therapeutically. Since metabotropic glutamate receptors are neuromodulatory in function, it is thought that drugs targeted to these receptors will be better tolerated clinically. Our goal is to understand the complexities and therapeutic potential of mGluR signaling in HD neurodegeneration. Recent evidence indicates that the huntingtin protein interacts with NMDARs and IPSRs, which are important downsteam targets of Group I mGluR signaling. The functional coupling of Group I mGluRs to these proteins is also potentiated by molecular crosslinks among these proteins involving the PSD protein homer. Furthermore, adenosine A2Areceptors (A2aRs) also form functional heterodimers with mGluRS, with the activity of one receptor potentiating the activity of the other. These receptor signaling mechanisms are particularly relevant to HD, as the striatal neurons most affected in the disease are some of the few cells in the brain that have high expression of both these receptors. The association of mGluRS with A2aRs in the context of mutant huntingtin is of yet unstudied. We hypothesize that the intermolecular interactions of mGluRs with related signaling molecules play an important role in the neurodegenerative process in HD. Therefore, we are examining the molecular and functional association of Group I mGluRs with A2aR, NMDAR andIP3R signaling proteins in the context the mutant huntingtin, aswell asthe direct interaction of Group I mGluRs with the huntingtin protein itself. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
4R37AG013617-11
Application #
7029231
Study Section
Special Emphasis Panel (NSS)
Program Officer
Petanceska, Suzana
Project Start
1995-08-15
Project End
2010-07-31
Budget Start
2005-08-15
Budget End
2006-07-31
Support Year
11
Fiscal Year
2005
Total Cost
$349,525
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ayala, Ramses; Kett, Lauren R; Leach, Tiffany L et al. (2012) Metabotropic glutamate receptor 1 (mGluR1): antibody specificity and receptor expression in cultured primary neurons. J Neurosci Methods 204:221-6
Benn, Caroline L; Luthi-Carter, Ruth; Kuhn, Alexandre et al. (2010) Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 69:817-27
Young, Anne B (2009) Four decades of neurodegenerative disease research: how far we have come! J Neurosci 29:12722-8
Orlando, Lianna R; Ayala, Ramses; Kett, Lauren R et al. (2009) Phosphorylation of the homer-binding domain of group I metabotropic glutamate receptors by cyclin-dependent kinase 5. J Neurochem 110:557-69
Benn, C L; Slow, E J; Farrell, L A et al. (2007) Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience 147:354-72
Zucker, Birgit; Luthi-Carter, Ruth; Kama, Jibrin A et al. (2005) Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet 14:179-89
Young, Anne B (2003) Huntingtin in health and disease. J Clin Invest 111:299-302
Orlando, L R; Dunah, A W; Standaert, D G et al. (2002) Tyrosine phosphorylation of the metabotropic glutamate receptor mGluR5 in striatal neurons. Neuropharmacology 43:161-73
Dunah, Anthone W; Jeong, Hyunkyung; Griffin, April et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238-43
Luthi-Carter, Ruth; Strand, Andrew D; Hanson, Sarah A et al. (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 11:1927-37

Showing the most recent 10 out of 19 publications